Could a modified protein help immunotherapy fight a tough breast cancer?

NCT ID NCT07698106

Not yet recruiting Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether adding isunakinra, a modified protein that blocks inflammation, can make triple-negative breast cancer more sensitive to standard immunotherapy and chemotherapy. The trial enrolls adults with newly diagnosed, locally advanced triple-negative breast cancer. Researchers will measure changes in the tumor environment to see if isunakinra helps the immune system attack the cancer more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isunakinra
What this could lead to: If it works, this could point toward a way to improve the effectiveness of immunotherapy for triple-negative breast cancer, potentially leading to better outcomes.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. The drug may not improve response or could cause additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.